Circumvent Pharmaceuticals

Executive Summary

Circumvent Pharmaceuticals is a private, Cambridge-based biotechnology company founded in 2019 with a mission to develop precision medicines for neurodegenerative diseases, starting with Batten disease. The company addresses a significant unmet medical need: neurodegenerative diseases are projected to become the second leading cause of death worldwide within two decades, yet progress in disease-modifying therapies has been hampered by a lack of mechanistic insights. Circumvent leverages novel biological understanding to target driver mechanisms underlying neurodegeneration. As a preclinical-stage company, Circumvent has yet to disclose specific pipeline assets or funding details, but its focus on precision medicine for Batten disease—a rare, fatal lysosomal storage disorder with no approved disease-modifying treatment for some forms—positions it within a high-need niche. The company's ability to differentiate from competitors will depend on its ability to translate its scientific platform into validated therapeutic candidates and advance them toward clinical trials.

Upcoming Catalysts (preview)

• Q4 2026Lead Program IND Filing40% success
• Q2 2026Series A Financing Announcement70% success
• Q3 2026Presentation of Preclinical Data at Major Conference60% success